Determining the long-term effect of antibiotic administration on the human normal intestinal microbiota using culture and pyrosequencing methods

Clinical Infectious Diseases

Volumn 60, Issue , 2015, Pages S77-S84

  Rashid, Mamun Ur ^a   Zaura, Egijia ^b   Buijs, Mark J ^b   Keijser, Bart J F ^c   Crielaard, Wim ^b   Nord, Carl Erik ^a   Weintraub, Andrej ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c TNO   (Netherlands)

Author keywords

antibiotics; culture; intestinal microbiota; pyrosequencing

Indexed keywords

CIPROFLOXACIN; CLINDAMYCIN; PLACEBO; ANTIINFECTIVE AGENT; RNA 16S;

ACTINOBACTERIA; ADULT; ARTICLE; BACTERIUM CULTURE; BACTEROIDETES; CLINICAL ARTICLE; CONTROLLED STUDY; CYANOBACTERIUM; DRUG EFFECT; DRUG EXPOSURE; FECES ANALYSIS; FECES MICROFLORA; FEMALE; FIRMICUTES; FUSOBACTERIA; HUMAN; LONG TERM EXPOSURE; MALE; MICROBIOME; MOLLICUTES; NORMAL HUMAN; PRIORITY JOURNAL; PROTEOBACTERIA; PYROSEQUENCING; TREATMENT DURATION; ANTIBIOTIC THERAPY; COPROCOCCUS; DOREA; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN EXPERIMENT; LACHNOSPIRACEAE; LACHOSPIRA; LONG TERM CARE; MICROBIAL DIVERSITY; ROSEBURIA; RUMINOCOCCUS; SPECIES COMPOSITION; ADOLESCENT; BACTERIAL COUNT; BACTERIAL LOAD; BACTERIUM; CLASSIFICATION; DRUG EFFECTS; FECES; GASTROINTESTINAL TRACT; GROWTH, DEVELOPMENT AND AGING; HIGH THROUGHPUT SEQUENCING; INTESTINE FLORA; ISOLATION AND PURIFICATION; MICROBIOLOGY; MIDDLE AGED; PATHOGENICITY; PEPTOCLOSTRIDIUM DIFFICILE; TIME; YOUNG ADULT;

ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL LOAD; CIPROFLOXACIN; CLINDAMYCIN; CLOSTRIDIUM DIFFICILE; COLONY COUNT, MICROBIAL; FECES; FEMALE; GASTROINTESTINAL MICROBIOME; GASTROINTESTINAL TRACT; HEALTHY VOLUNTEERS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MALE; MIDDLE AGED; PLACEBOS; RNA, RIBOSOMAL, 16S; TIME FACTORS; YOUNG ADULT;

EID: 84928880862     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/civ137     Document Type: Article

References (33)

1. Duncan SH, Louis P, Flint HJ. Cultivable bacterial diversity from the human colon. Lett Appl Microbiol 2007; 44: 343-50.
2. Flint HJ, Duncan SH, Scott KP, Louis P. Interactions and competition within the microbial community of the human colon: links between diet and health. Environ Microbiol 2007; 9: 1101-11.
3. Iebba V, Aloi M, Civitelli F, Cucchiara S. Gut microbiota and pediatric disease. Dig Dis 2011; 29: 531-9.
4. Tiihonen K, Ouwehand AC, Rautonen N. Human intestinal microbiota and healthy ageing. Ageing Res Rev 2010; 9: 107-16.
5. Tlaskalova-Hogenova H, Stepankova R, Hudcovic T, et al. Commensal bacteria (normal microflora), mucosal immunity and chronic inflammatory and autoimmune diseases. Immunol Lett 2004; 93: 97-108.
6. Rashid MU, Weintraub A, Nord CE. Effect of new antimicrobial agents on the ecological balance of human microflora. Anaerobe 2012; 18: 249-53.
7. Sullivan A, Edlund C, Nord CE. Effect of antimicrobial agents on the ecological balance of human microflora. Lancet Infect Dis 2001; 1: 101-14.
8. Reeder J, Knight R. Rapidly denoising pyrosequencing amplicon reads by exploiting rank-abundance distributions. Nat Methods 2010; 7: 668-9.
9. Su C, Lei L, Duan Y, Zhang KQ, Yang J. Culture-independent methods for studying environmental microorganisms: methods, application, and perspective. Appl Microbiol Biotechnol 2012; 93: 993-1003.
10. Gagen EJ, Huber H, Meador T, Hinrichs KU, Thomm M. Novel cultivation-based approach to understanding the miscellaneous crenarchaeotic group (MCG) archaea from sedimentary ecosystems. Appl Environ Microbiol 2013; 79: 6400-6.
11. Gorbach SL, Barza M, Giuliano M, Jacobus NV. Colonization resistance of the human intestinal microflora: testing the hypothesis in normal volunteers. Eur J Clin Microbiol Infect Dis 1988; 7: 98-102.
12. LeBel M. Ciprofloxacin: chemistry, mechanism of action, resistance, antimicrobial spectrum, pharmacokinetics, clinical trials, and adverse reactions. Pharmacotherapy 1988; 8: 3-33.
13. Rashid M, Weintraub A, Nord CE. Comparative effects of the immediate and the extended release formulations of ciprofloxacin on normal human intestinal microflora. J Chemother 2011; 23: 145-9.
14. Brismar B, Edlund C, Malmborg AS, Nord CE. Ciprofloxacin concentrations and impact of the colon microflora in patients undergoing colorectal surgery. Antimicrob Agents Chemother 1990; 34: 481-3.
15. Dang V, Nanda N, Cooper TW, Greenfield RA, Bronze MS. Part VII. Macrolides, azalides, ketolides, lincosamides, and streptogramins. J Okla State Med Assoc 2007; 100: 75-81.
16. Kager L, Liljeqvist L, Malmborg AS, Nord CE. Effect of clindamycin prophylaxis on the colonic microflora in patients undergoing colorectal surgery. Antimicrob Agents Chemother 1981; 20: 736-40.
17. Nord CE, Sillerstrom E, Wahlund E. Effect of tigecycline on normal oropharyngeal and intestinal microflora. Antimicrob Agents Chemother 2006; 50: 3375-80.
18. Versalovic J, Carroll KC, Funke G, Jorgensen J, Landry ML, Warnock DW, eds. Manual of clinical microbiology. 10th ed. Washington, DC: ASM Press, 2011.
19. Zaura E, Keijser BJ, Huse SM, Crielaard W. Defining the healthy "core microbiome" of oralmicrobial communities. BMC Microbiol 2009; 9: 259.
20. Kraneveld EA, Buijs MJ, Bonder MJ, et al. The relation between oral Candida load and bacterial microbiome profiles in Dutch older adults. PLoS One 2012; 7: e42770.
21. Caporaso JG, Kuczynski J, Stombaugh J, et al. QIIME allows analysis of high-throughput community sequencing data. Nat Methods 2010; 7: 335-6.
22. Hammer O, Harper DAT, Ryan PD. PAST: Paleontological statistics software package for education and data analysis. Palaeontologia Electronica 2001; 4: 1-9.
23. Brook I. The role of anaerobic bacteria in bacteremia. Anaerobe 2010; 16: 183-9.
24. Clarke JS. Bacteriology of the gut and its clinical implications. West J Med 1974; 121: 390-403.
25. Garcia-Sanchez JE, Jose Fresnadillo M, Garcia-Sanchez E. New anaerobic bacterial species in human infections [in Spanish]. Enferm Infecc Microbiol Clin 2010; 28: 173-84.
26. Stoddart B, Wilcox MH. Clostridium difficile. Curr Opin Infect Dis 2002; 15: 513-8.
27. Talpaert MJ, Gopal Rao G, Cooper BS, Wade P. Impact of guidelines and enhanced antibiotic stewardship on reducing broad-spectrum antibiotic usage and its effect on incidence of Clostridium difficile infection. J Antimicrob Chemother 2011; 66: 2168-74.
28. Owens RC Jr, Donskey CJ, Gaynes RP, Loo VG, Muto CA. Antimicrobial-associated risk factors for Clostridium difficile infection. Clin Infect Dis 2008; 46(suppl 1): S19-31.
29. Goldstein EJ. Beyond the target pathogen: ecological effects of the hospital formulary. Curr Opin Infect Dis 2011; 24(suppl 1): S21-31.
30. Deshpande A, Pant C, Jain A, Fraser TG, Rolston DD. Do fluoroquinolones predispose patients to Clostridium difficile associated disease? A review of the evidence. Curr Med Res Opin 2008; 24: 329-33.
31. Weiss K. Clostridium difficile and fluoroquinolones: is there a link? Int J Antimicrob Agents 2009; 33(suppl 1): S29-32.
32. Vassallo A, Tran MC, Goldstein EJ. Clostridium difficile: improving the prevention paradigm in healthcare settings. Expert Rev Anti Infect Ther 2014; 12: 1087-102.
33. Novell MJ, Morreale CA. The relationship between inpatient fluoroquinolone use and Clostridium difficile-associated diarrhea. Ann Pharmacother 2010; 44: 826-31.